Introduction
============

Nonalcoholic fatty liver disease (NAFLD) is caused by excessive fat accumulation in the liver and can lead to progressive fibrosis and liver cirrhosis. Progression to irreversible, end-stage liver disease could result in liver transplantation \[[@b1-kjp-2018-06786],[@b2-kjp-2018-06786]\]. So, early detection and effective treatment is important. The Korea National Health and Nutrition Examination Survey \[[@b3-kjp-2018-06786]\] reported 8.9% of NAFLD prevalence in children.

Obesity is known as the leading risk factor for NAFLD and screening is recommended for obese children and for overweight children with additional risk factors such as dyslipidemia, insulin resistance, central obesity \[[@b4-kjp-2018-06786],[@b5-kjp-2018-06786]\]. However, some children with NAFLD are not obese.

Besides obesity, other clinical and laboratory factors may be contributed to NAFLD. Das et al. \[[@b6-kjp-2018-06786]\] reported the importance of body fat percentage suggesting normal body mass index (BMI) could be an independent risk factor for NAFLD. Recent study \[[@b7-kjp-2018-06786]\] identifying factors associated alanine aminotransferase (ALT) elevation; truncal obesity and obesity were significant independent predictors. Significant role of low levels of serum 25-hydroxyvitamin D in NAFLD was also reported independent of metabolic syndrome \[[@b8-kjp-2018-06786],[@b9-kjp-2018-06786]\].

Nonobese NAFLD ranges from 12% to 16% in Korean adults \[[@b10-kjp-2018-06786]-[@b12-kjp-2018-06786]\]. In the United States, NAFLD ranges from 38% in obese to 9.6% in children with normal-weight \[[@b13-kjp-2018-06786]\].

Despite, nonobese individuals account for a substantial proportion of NAFLD, less is known about this population, especially in pediatric patients.

This study aimed to evaluate the prevalence of nonobese patients in pediatric NAFLD and compare clinical characteristics of obese with NAFLD.

Materials and methods
=====================

1. Study population
-------------------

Patients diagnosed with NAFLD between January 2010 and October 2016 at 10--17 years of age were included in this study. We retrospectively analyzed the data using the electronic medical records of patients. NAFLD was diagnosed on the basis of the bright or hyperechoic lesions on liver imaging and ALT level ≥30 IU/L with the exclusion of other diseases; autoimmune hepatitis, viral hepatitis, Wilson disease, history of hepatotoxic drugs \[[@b4-kjp-2018-06786],[@b13-kjp-2018-06786],[@b14-kjp-2018-06786]\]. Institutional Review Board (IRB) of Inje University Busan Paik Hospital approval was obtained in this retrospective study (approval number: 17-0080). The requirement for informed consent was exempted by the IRB.

2. Clinical and biochemical evaluation
--------------------------------------

BMI was calculated by using height and body weight that was measured by a trained technician. Waist circumference was measured at the midpoint between the edge of the last rib and iliac crest by a flexible measuring tape (1-mm accuracy).

The laboratory evaluation was performed after patients had fasted overnight and included measurement of aspartate aminotransferase (AST), ALT, γ-glutamyl transferase (γ-GTP), total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, fasting blood glucose, uric acid, and 25-hydroxyvitamin D.

Asian populations use the different BMI cutoff points and we defined obesity as a BMI ≥95th percentile for age and sex or BMI ≥25 kg/m^2^. A BMI ≥85th but \<95th percentile or BMI 22.5--24.9 kg/m^2^ was defined as "overweight" \[[@b15-kjp-2018-06786]-[@b17-kjp-2018-06786]\]. Waist circumference ≥90th percentile for age and sex was defined as abdominal obesity \[[@b18-kjp-2018-06786]\].

Among the different cutoff values for laboratory profiles to lipid and blood glucose, we used the reference values of International Diabetes Federation for fasting glucose, triglyceride, and HDL cholesterol \[[@b18-kjp-2018-06786]\]. For LDL cholesterol and total cholesterol, we used the reference values of The National Heart, Lung, and Blood Institute \[[@b19-kjp-2018-06786]\].

Abnormal laboratory concentrations were defined as follows \[[@b18-kjp-2018-06786],[@b19-kjp-2018-06786]\]; Fasting glycemia ≥100 mg/dL, triglycerides ≥150 mg/dL, LDL cholesterol \>130 mg/day, HDL cholesterol \<40 mg/dL (\<50 mg/dL in 2female over 16 years), and total cholesterol ≥200 mg/dL. Uric acid level of ≥6.5 mg/dL in female or ≥7 mg/dL in male was defined as hyperuricemia \[[@b20-kjp-2018-06786]\].

1-25 dihydroxyvitamin D could be regulated by calcium, parathyroid hormone and we measured 25-hydroxyvitamin D, which is considered as a best available indicator of vitamin D status \[[@b21-kjp-2018-06786]\].

Liver imaging were performed by a specialized one radiologist and grading of the fat infiltration was recorded as mild, moderate, and severe \[[@b22-kjp-2018-06786]\].

3. Statistical analysis
-----------------------

Continuous data were expressed as the median or mean±standard deviation and interquartile range. They were compared using the Mann-Whitney *U* test or Student t test. Discrete data were expressed as numbers and percentages and compared using Fisher exact or chi-square tests. To evaluate risk factors associated with the NAFLD, we used the hazard ratios (HRs) of the logistic regression models. A P value of \<0.05 was considered statistically significant. All prognostic variables with a *P* value of \<0.1 in univariate analysis were included in the multivariate analysis. Statistical analyses were performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA).

Results
=======

1. Baseline characteristics of NAFLD
------------------------------------

Of the 68 patients included in this study, 58 (85.3%) were males, and 10 (14.7%) were females. The median age at diagnosis was 13 years (range, 10--17 years) and the ratio of male-to female ratio was 5.8:1. Mean triglyceride level (182.1 mg/dL) was higher than the normal range; however, mean 25-hydroxyvitamin D level (25.6 ng/mL) was within the normal range. Mean uric acid level (6.8 mg/dL) was in the upper normal range. Approximately, 60% and 30% of patients had increased levels of triglyceride and uric acid, respectively. According to ultrasonographic findings, mild, moderate, and severe grade was shown in 22 (55.5%), 27 (40%), and 19 patients (4.5 %), respectively. The baseline characteristics of the NAFLD patients are shown in [Table 1](#t1-kjp-2018-06786){ref-type="table"}.

2. Differences between obese and nonobese patients
--------------------------------------------------

Of the 68 patients, 42 (61.8%) were obese, and 26 (38.2%) were nonobese. Among the nonobese patients, 10 (38.5%) were normal-weight and 16 (61.5%) were overweight patients. Males were predominant in both groups, and median age at diagnosis was similar between groups.

Significant higher triglyceride (223.0 mg/dL vs. 145.9 mg/dL, *P*=0.047) and total cholesterol levels (211.6 mg/dL vs. 173.2 mg/dL, *P*=0.011) were shown in nonobese than obese patients. Normal-weight patients had significantly lower HDL cholesterol levels (35.4 mg/dL vs. 48.2 mg/dL, *P*=0.023) than overweight patients. When compared with obesity patients, normal-weight patients had significantly lower HDL cholesterol (35.4 mg/dL vs. 46.8 mg/dL, P=0.004) and higher triglyceride levels (275.3 mg/dL vs. 145.9 mg/dL, *P*=0.005). Uric acid and 25-hydroxyvitamin D levels did not differ between groups. Mild ultrasonographic grade (46.1% vs. 23.8%) was more common in nonobese and moderate ultrasonographic grade (23.1% vs. 50.0%) was more common in obese patients. However, significant difference was not noted.

Abdominal obesity was shown in 42 (100%) of obese and 18 (69.2%) of nonobese patients. The clinical characteristics of NAFLD patients classified as obese and nonobese are shown in [Table 1](#t1-kjp-2018-06786){ref-type="table"}, and classified as obese, overweight, and normal-weight are shown in [Table 2](#t2-kjp-2018-06786){ref-type="table"}.

3. Factors associated with NAFLD in nonobese patients
-----------------------------------------------------

In univariate analysis, total cholesterol level \>200 mg/dL (HR, 5.6; 95% CI, 1.23--15.31; *P*=0.038), HDL cholesterol level \<40 mg/dL (HR, 6.5; 95% CI, 2.13--7.10; *P*=0.048) and abdominal obesity (HR, 2.53; 95% CI, 1.22--4.68; *P*=0.013) were significant risk factors for NAFLD in nonobese patients. However, in multivariate analysis, only abdominal obesity (HR, 2.14; 95% CI, 0.86--5.68; *P*=0.025) was associated significantly with NALFD in nonobese patients. [Table 3](#t3-kjp-2018-06786){ref-type="table"} shows risk factors associated with the NAFLD in nonobese patients.

Discussion
==========

The prevalence of NAFLD is increasing with parallel with obesity rates. Younossi et al. \[[@b23-kjp-2018-06786]\] reported the middle east as the highest prevalence area for NAFLD and 25.24% of global NAFLD prevalence. However, NAFLD also has been reported in nonobese patients, with higher mortality and more severe histological necroinflammation than in the obese \[[@b24-kjp-2018-06786]\].

In our study, 26 NAFLD patients (38.2%) were nonobese. Although our sample size is small, nonobese patients were more common than have been reported in previous studies \[[@b12-kjp-2018-06786],[@b20-kjp-2018-06786],[@b25-kjp-2018-06786]\] of adults. Higher total cholesterol and triglyceride levels were observed in nonobese patients than in obese, and HDL cholesterol level of \<40 mg/dL was risk factor for NAFLD in nonobese patients. Sex, age and biochemical parameters including 25-hydroxyvitamin D and uric acid did not different significantly between the 2 groups.

The male predominance in this study, with ratio of 5.8:1, similar to that reported in other studies \[[@b26-kjp-2018-06786],[@b27-kjp-2018-06786]\]. This result may be a consequence of the efficacy of estrogen suppresses visceral fat accumulation \[[@b28-kjp-2018-06786]\]. The male-to-female ratio and median age of diagnosis did not differ between the 2 groups.

Recently, abnormal uric acid levels have been identified as risk factor of NAFLD. Wijarnpreecha et al. \[[@b29-kjp-2018-06786]\] detected a positive association between NAFLD and increased uric acid levels. Although the development of NAFLD is a complex and multifactorial process, insulin resistance is an important contributing factor. Insulin resistance leads to hyperinsulinemia, which reduces uric acid renal excretion and increases synthesis of uric acid \[[@b30-kjp-2018-06786],[@b31-kjp-2018-06786]\]. So, the association between NAFLD and serum uric acid levels could be explained by hyperinsulinemia.

In this study, hyperuricemia was not detected in NAFLD. However, mean uric acid levels were in the upper-normal range for both groups. A previous study \[[@b32-kjp-2018-06786]\] also reported that upper-normal range uric acid level was independently associated with NAFLD.

Previous studies \[[@b10-kjp-2018-06786],[@b11-kjp-2018-06786]\] those conducted in adult nonobese patients with NAFLD reported higher levels of triglyceride and lower levels of HDL cholesterol were associated significantly with nonobese patients. Similar to these studies, abnormal triglyceride and HDL-cholesterol levels were significantly associated with nonobese in our study, especially in normal weight patients.

Meta-analysis by Pang et al. \[[@b33-kjp-2018-06786]\] reported the significant role of central obesity on NAFLD independent of Obesity. In our study, abdominal obesity is significant risk factor for nonobese NAFLD. Waist circumference should be measured for early detection of NAFLD who had normal BMI.

This study has some limitations. First, the patients were from a single center, which may not be generalizable to all populations. The retrospective design of the study also may have introduced bias. Second, we did not have data from liver biopsies and therefore could not assess pathological severity and histological finding. However, most parents refuse this invasive procedure, and ultrasonography is considered sufficient for the diagnosis of NAFLD. Third, we did not have data concerning insulin resistance, the influence of pubertal development has not been assessed, and lysosomal acid lipase activity abnormality that recently considered as a cause of liver steatosis was not excluded in nonobese patients. However, the present study is the first in an Asian pediatric population to assess the incidence of nonobese NAFLD and differences between obese and nonobese patients. Future well-designed prospective population-based studies could resolve potential bias in these results.

In conclusion, nonobese patients present a substantial proportion of pediatric NAFLD cases.

Significant abnormal lipid concentrations were found and abdominal obesity was important risk factor for nonobese NAFLD.
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###### 

Baseline characteristics of nonobese and obese patients with nonalcoholic fatty liver disease

  Variable                      Total (n=68)   Nonobese (n=26)   Obese (n=42)   *P* value
  ----------------------------- -------------- ----------------- -------------- -----------
  Age (yr)                      13 (10--17)    13 (10--17)       13 (10--17)    0.703
  Male sex                      58 (85.3)      24 (92.3)         34 (80.9)      0.627
  Abdominal obesity             60 (88.2)      18 (69.2)         42 (100)       0.053
  Total cholesterol (mg/dL)     188.3±40.6     211.6±38.1        173.2±35.5     0.011
  Triglyceride (mg/dL)          182.1±89.5     223.0±107.6       145.9±63.9     0.047
  LDL cholesterol (mg/dL)       121.9±33.8     129.4±37.2        115.4±30.3     0.299
  HDL cholesterol (mg/dL)       45.0±8.6       42.4±9.9          46.8±7.3       0.200
  Fasting glucose (mg/dL)       93.2±8.2       85.3±7.5          90.2±8.5       0.153
  AST (IU/L)                    82.7±72.9      90.8±55.7         77.5±83.3      0.618
  ALT (IU/L)                    168.8±152.7    169.3±124.8       168.5±171.5    0.988
  γ-GTP (IU/L)                  50.5±31.5      35.4±32.4         42.3±30.5      0.258
  25-Hydroxyvitamin D (ng/mL)   25.6±14.0      24.5±13.6         26.7±15.6      0.798
  Uric acid (mg/dL)             6.8±1.9        6.7±1.8           6.9±2.2        0.305
  Ultrasonographic grade                                                        0.244
   Mild                         22 (32.4)      12 (46.1)         10 (23.8)      
   Moderate                     27 (39.7)      6 (23.1)          21 (50.0)      
   Severe                       19 (27.9)      8 (30.8)          11 (26.2)      

Values are presented as a median (range), number (%), and mean±standard deviation.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transferase.

###### 

Baseline characteristics of normal-weight, overweight, and obese patients with nonalcoholic fatty liver disease

  Variable                      Normal (n=10)   Overweight (n=16)   Obese (n=42)   *P* value
  ----------------------------- --------------- ------------------- -------------- -----------
  Age (yr)                      13 (10--17)     13 (10--17)         13 (10--17)    0.853
  Male sex                      8 (80)          16 (100)            34 (80.9)      0.230
  Abdominal obesity             2 (20)          16 (100)            42 (100)       0.033
  Total cholesterol (mg/dL)     196.0±30.6      220.6±41.4          173.2±35.5     0.025
  Triglyceride (mg/dL)          275.3±85.6      193.1±13.1          145.9±63.9     0.042
  LDL cholesterol (mg/dL)       127.0±25.6      131.1±45.7          115.3±30.3     0.577
  HDL cholesterol (mg/dL)       35.4±4.3        48.2±9.6            46.8±7.3       0.014
  Fasting glucose (mg/dL)       83.2±8.2        86.5±7.8            90.2±8.5       0.089
  AST (IU/L)                    98.0±48.3       86.3±62.6           77.5±83.3      0.852
  ALT (IU/L)                    172.6±109.7     167.3±140.7         168.5±171.5    0.998
  γ-GTP (IU/L)                  40.2±38.2       38.0±33.5           42.3±30.5      0.178
  25-hydroxyvitamin D (ng/mL)   22.5±16.5       28.5±8.4            26.7±15.6      0.876
  Uric acid (mg/dL)             6.9±1.4         6.3±3.2             6.9±2.2        0.525
  Ultrasonographic grade                                                           0.185
   Mild                         4 (40.0)        8 (50.0)            10 (23.8)      
   Moderate                     3 (30.0)        3 (18.8)            21 (50.0)      
   Severe                       3 (30.0)        5 (31.2)            11 (26.2)      

Values are presented as a median (range), number (%), and mean±standard deviation.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transferase.

###### 

Univariate and multivariate Cox analysis for risk factors of nonalcoholic fatty liver disease in nonobese patients

  Variable                        Univariate analysis    *P* value   Multivariate analysis   *P* value
  ------------------------------- ---------------------- ----------- ----------------------- -----------
  Male sex                        2.82 (0.280--28.518)   0.215       \-                      
  Abdominal obesity               2.53 (1.224--4.688)    0.013       2.14 (0.867--5.688)     0.025
  Total cholesterol \>200 mg/dL   5.64 (1.230--15.319)   0.038       1.96 (0.247--15.661)    0.523
  Triglyceride \>150 mg/dL        2.32 (0.465--10.883)   0.313       \-                      
  LDL cholesterol \>130 mg/dL     1.25 (0.225--6.383)    0.442       \-                      
  HDL cholesterol \<40 mg/dL      6.56 (2.136--7.106)    0.048       5.46 (0.689--43.288)    0.108
  Fasting glucose \>100 mg/dL     1.02 (1.005--1.056)    0.546       \-                      
  25-OH vitamin D \<20 ng/mL      0.78 (0.060--7.352)    0.741       \-                      
  Hyperuricemia                   0.63 (0.068--4.672)    0.594       \-                      

Values are presented as hazard ratio (95% confidence interval).

LDL, low-density lipoprotein; HDL, high-density lipoprotein; 25-OH vitamin D, 25-hydroxyvitamin D.
